Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Weiner, G. Kuo, C. Lee, Jody Rosenblatt, Q. Choo, M. Houghton, D. Bradley, F. Bonnino, G. Saracco (1990)
Detection of hepatitis C viral sequences in non-A, non-B hepatitisThe Lancet, 335
C. Poel, H. Reesink, J. Boven, H. Cuypers, I. Winkel, P. Exel-Oehlers, W. Schaasberg, P. Lelie, A. Weiner, A. Polito, S. Quan, R. Nello, M. Houghton, D. Mulder-Folkerts, A. Leentvaar‐Kuypers (1991)
Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assayThe Lancet, 337
M. Thaler, D. Wara, G. VEEREMAN-WAUTERS, Daniel Landers, Richard Sweet, C. Park, M. Houghton, JANG Han (1991)
Vertical transmission of hepatitis C virusThe Lancet, 338
Q. Choo, A. Weiner, L Overby, G. Kuo, M. Houghton, D. Bradley (1990)
Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis.British medical bulletin, 46 2
H. Alter, R. Purcell, J. Shih, J. Melpoller, I. Houghton, Q. Choo, G. Kus (1990)
Detection of Antibody to Hepatitis C Virus in Prospectively Followed Transfusion Recipients with Acute and Chronic Non-A, Non-B HepatitisSurvey of Anesthesiology, 34
G. Kuo, Q. Choo, H. Alter, G. Gitnick, A. Redeker, R. Purcell, T. Miyamura, J. Dienstag, M. Alter, C. Stevens (1989)
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitisScience, 244
J. Esteban, António Gonzalez, J. Hernández, L. Viladomiu, C. Sánchez, J. López-Talavera, D. Lucea, C. Martín‐Vega, X. Vidal, R. Esteban, J. Guardia (1990)
Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis.The New England journal of medicine, 323 16
H. Alter, R. Purcell, J. Shih, J. Melpolder, M. Houghton, Q. Choo, G. Kuo (1989)
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.The New England journal of medicine, 321 22
Q. Choo, K. Richman, Jang Han, K. Berger, C. Lee, Christine Dong, C. Gallegos, D. Coit, R. Medina-Selby, P. Barr (1991)
Genetic organization and diversity of the hepatitis C virus.Proceedings of the National Academy of Sciences of the United States of America, 88
(1988)
Non-A, non-B posttransfusion hepatitis in open heart surgery patients in the Netherlands: Preliminary results of a prospective study
L. Mimms, D. Vallari, L. Ducharme, P. Holland, I. Kuramoto, J. Zeldis (1990)
Specificity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regionsThe Lancet, 336
Jang Han, V. Shyamala, K. Richman, Matthew Brauer, B. Irvine, M. Urdea, P. Tekamp-Olson, G. Kuo, Q. Choo, M. Houghton (1991)
Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end.Proceedings of the National Academy of Sciences of the United States of America, 88 5
H. Cuypers, I. Winkel, C. Poel, H. Reesink, P. Lelie, M. Houghton, A. Weiner (1991)
Analysis of genomic variability of hepatitis C virus.Journal of hepatology, 13 Suppl 4
Q. Choo, G. Kuo, A. Weiner, L. Overby, D. Bradley, M. Houghton (1989)
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.Science, 244 4902
C. Poel, H. Reesink, W. Schaasberg, E. Bakker, P. Exel-Oehlers, P. Lelie, A. Leentvaar‐Kuypers (1990)
Infectivity of blood seropositive for hepatitis C virus antibodiesThe Lancet, 335
A semiautomated dot blot assay and cDNA polymerase chain reaction (PCR) were used to study longitudinal anti‐hepatitis C virus (HCV) recognition patterns i n relation to presence of HCV‐RNA in transfusion recipients and their infectious donors. In 9 recipients, 4 different patterns of HCV infection were observed: (A) persistent HCV carriage accompanied by chronic hepatitis in 6, (B) acute resolved hepatitis, but persistent HCV replication in one, and (C) continuous HCV replication without hepatitis in one and (D) acute resolved hepatitis with clearance of infection in one. This last self‐limited infection was characterized by the disappearance of HCV‐RNA as well as anti‐HCV reactivity. In contrast, antibody reactivity persisted in 7 of 8 patients with chronic HCV infection who could be followed until 1990. Seven of the 9 recipients developed antibodies to all recombinant peptides in dot blot assay; one became positive for anti‐C33 and anti‐core and one developed anti‐core only. The sequence of appearance of antibodies differed among individual patients. In 7 patients with full anti‐HCV recognition patterns, the sequence of events was (mean and limits in days after transfusion): onset of hepatitis at day 50 (22–74), seroconversion of anti‐C33 at day 91 (59–129), anti‐core at day 133 (54–203), and anti‐C100 at day 143 (59–365). The incorporation of C33 and core proteins, in addition to C100, in the second generation anti‐HCV ELISA enhanced the detection rate in the HCV‐infected transfusion recipients from 7/9 (78%) to 9/9 (100%). In 4 of the 7 anti‐C100 seroconverters anti‐HCV was detectable 38–277 days earlier in the new ELISA. However, the development of anti‐HCV in the second‐generation ELSA was still delayed (54–192 (mean 103) days after transfusion and 0–135 (mean 53) days after onset of hepatitis). We conclude that combined application of anti‐HCV immunoblot techniques and cDNA‐PCR in consecutive samples is necessary for reliable diagnosis of either ongoing productive or resolving HCV infection. © 1992 Wiley‐Liss, Inc.
Journal of Medical Virology – Wiley
Published: Jul 1, 1992
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.